Condition: Prostate Cancer · Sponsor: ABX advanced biochemical compounds GmbH
This study assess the Diagnostic Performance of \[18F\]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer
This description comes directly from the study's public registry record.
Alexander Hoepping, Dr. · +49 3528 4041 60 · cd@abx.de
Always discuss trial participation with your own doctor first.
| CHRU de Nancy | Nancy, France | Recruiting |
| Carl Gustav Carus Faculty of Medicine, TUD Dresden | Dresden, Germany | Recruiting |
| University Hospital Düsseldorf | Düsseldorf, Germany | Recruiting |
| St. Antonius Hospital | Gronau, Germany | Recruiting |
| University Hospital Hamburg-Eppendorf | Hamburg, Germany | Recruiting |
| University Hospital Leipzig | Leipzig, Germany | Recruiting |
| Klinikum rechts der Isar, TUM | München, Germany | Active Not Recruiting |
| University Hospital Münster | Münster, Germany | Recruiting |
| Universitätsmedizin Rostock | Rostock, Germany | Recruiting |
| IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" | Meldola, Italy | Recruiting |
| IRCCS Ospedale Sacro Cuore-Don Calabria | Verona, Italy | Recruiting |
| The University of Osaka Hospital | Osaka, Japan | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06122584